Market Overview

Sangamo Presents Data From ZFP Therapeutic Program for Treatment Of Sickle Cell Disease And Beta-Thalassemia at ASH


Sangamo BioSciences (Nasdaq: SGMO) announced the presentation of preclinical data from its ZFP Therapeutic program for the treatment and potential cure of both sickle cell disease (SCD) and beta-thalassemia. The data demonstrate that Sangamo's approach, using its proprietary and highly specific zinc finger nuclease (ZFN) gene-editing technology, enables permanent increase in the expression of fetal gamma-globin in adult red blood cells (RBCs). This increase restores the normal balance of globin proteins that together form the oxygen-carrying hemoglobin of RBCs. In addition, the pre-clinical studies demonstrate that this can be accomplished at clinical-scale reproducibly achieving high levels (up to 80 percent) of gene editing in hematopoietic stem cells (HSCs).#ASH13

See full press release

Posted-In: News Guidance Offerings Management Global


Related Articles (SGMO)

View Comments and Join the Discussion!

Acorda Presents New Diazepam Nasal Spray Data at 67th Annual Meeting of American Epilepsy Society

MiMedx Group Announces 5M Share Offering